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Abstract
Background: Approximately 20% of patients experience chronic pain after total knee replacement. There is little
evidence for effective interventions for the management of this pain, and current healthcare provision is patchy and
inconsistent. Given the complexity of this condition, multimodal and individualised interventions matched to pain
characteristics are needed. We have undertaken a comprehensive programme of work to develop a care pathway for
patients with chronic pain after total knee replacement. This protocol describes the design of a randomised controlled
trial to evaluate the clinical- and cost-effectiveness of a complex intervention care pathway compared with usual care.
Methods: This is a pragmatic two-armed, open, multi-centred randomised controlled trial conducted within secondary
care in the UK. Patients will be screened at 2 months after total knee replacement and 381 patients with chronic pain
at 3 months postoperatively will be recruited. Recruitment processes will be optimised through qualitative research
during a 6-month internal pilot phase. Patients are randomised using a 2:1 intervention:control allocation ratio. All
participants receive usual care as provided by their hospital. The intervention comprises an assessment clinic
appointment at 3 months postoperatively with an Extended Scope Practitioner and up to six telephone follow-up calls
over 12 months. In the assessment clinic, a standardised protocol is followed to identify potential underlying causes for
the chronic pain and enable appropriate onward referrals to existing services for targeted and individualised treatment.
Outcomes are assessed by questionnaires at 6 and 12 months after randomisation. The co-primary outcomes are pain
severity and pain interference assessed using the Brief Pain Inventory at 12 months after randomisation. Secondary
outcomes relate to resource use, function, neuropathic pain, mental well-being, use of pain medications, satisfaction
with pain relief, pain frequency, capability, health-related quality of life and bodily pain. After trial completion, up to 30
patients in the intervention group will be interviewed about their experiences of the care pathway.
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Discussion: If shown to be clinically and cost-effective, this care pathway intervention could improve the management
of chronic pain after total knee replacement.
Trial registration: ISRCTN registry (ISRCTN92545361), prospectively registered on 30 August 2016.
Keywords: Total knee replacement, Chronic post-surgical pain, Care pathway, Randomised controlled trial
Background
Treatment of osteoarthritis with total knee replacement
aims to reduce pain, functional limitations and associ-
ated disability. Over 100,000 primary total knee replace-
ments were performed in the United Kingdom (UK) in
2015 [1, 2]. Despite good outcomes for many, a system-
atic review found that approximately 20% of patients
report chronic pain after total knee replacement [3].
Chronic post-surgical pain is defined as pain that occurs
or increases in intensity at 3 months or longer after sur-
gery [4]. Patients with bothersome pain at 3 months
after surgery are often disappointed with their outcome
[5, 6], feel abandoned by healthcare [7] and struggle to
make sense of ongoing pain [8]. Chronic pain after knee
replacement is an under-investigated area, but the wider
literature shows the impact of chronic pain on all areas
of life. Chronic pain is associated with poor general
health, interference with daily activities, disability and
depression [9–11]. Compared with the general popula-
tion, patients with chronic musculoskeletal pain report
lower satisfaction with life [12–14]. Older people with
pain are likely to become socially isolated, which is a risk
factor for other problems [15], limiting their capacity to
bring about change or to seek help for their pain.
Healthcare provision for patients with chronic pain
after total knee replacement has been shown to be
patchy and inconsistent in the UK, with only some
orthopaedic centres having standardised protocols to
guide the assessment and management of patients with
this condition [16]. A systematic review identified that
only one trial has evaluated an intervention for the man-
agement of chronic pain after knee replacement – an in-
jection with antinociceptive and anticholinergic activity
[17]. There is also insufficient evidence about the effect-
iveness of interventions for the management of chronic
pain after any surgery type [18]. Therefore, there is a
need for robust evidence to guide the early screening,
identification and management of patients with chronic
pain after total knee replacement.
Treatment of chronic pain is challenging, and evalu-
ation of treatments in combination or matched to
patient characteristics is advocated [19], yet no such tri-
als have been evaluated in the context of chronic post-
surgical pain [18]. It has been argued that rather than
new interventions for pain, improvements are re-
quired to access existing treatments with combination
treatments matched to pain characteristics [19].
Chronic pain after total knee replacement may be
caused by biological and mechanical factors. Bio-
logical causes include the sensitising impact of chronic
pain from osteoarthritis [20–22], development of Complex
Regional Pain Syndrome [23–25], persistent postoperative
inflammation, infection and/or localised nerve injury [26].
Mechanical causes include altered gait, prosthesis loosen-
ing, and weakening effects on ligaments [27, 28]. Psycho-
logical factors may also influence postoperative outcomes
[29].
To improve the management of chronic pain after
total knee replacement, we have developed the STAR
(Support and Treatment After joint Replacement) care
pathway [30], which consists of early postoperative
screening to identify patients with pain and an assessment
clinic at 3 months postoperatively with an Extended Scope
Practitioner and telephone follow-up, as required. The
intervention aims to enable appropriate onwards referral
to existing services to ensure that underlying reasons for
chronic pain are considered early in the postoperative
pathway and that treatment is targeted at these to improve
pain management and to reduce the impact of pain. In
line with UK Medical Research Council guidance on com-
plex interventions, comprehensive development work has
been undertaken to design and refine this intervention.
The design of the intervention is underpinned by a sys-
tematic review [17], survey of current practice [16], focus
groups with health professionals [31], expert deliberation
and patient involvement activities [32]. Further develop-
ment and refinement work included consensus work with
health professionals to refine intervention content, testing
intervention delivery and acceptability to patients, and
evaluation of views about implementation of the interven-
tion within the context of a randomised controlled trial
[30]. The aim of this multi-centre randomised controlled
trial is to evaluate the clinical and cost-effectiveness of the
care pathway for patients with chronic pain after total
knee replacement.
Methods/Design
This protocol follows guidance from SPIRIT (Standard
Protocol Items: Recommendations for Interventional Trials)
[33, 34]. A SPIRIT figure for the schedule of enrolment,
interventions and assessment is provided in Fig. 1 and a
SPIRIT checklist is provided in Additional file 1.
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Aim
The primary aim of this trial is to evaluate the clinical
effectiveness of a new care pathway (‘the STAR path-
way’) when compared with usual care for people with
chronic pain after knee replacement. Secondary objec-
tives of embedded aspects of the trial include:
1. Pilot phase with qualitative work to optimise
recruitment and refine trial processes;
2. Economic analysis to evaluate the cost-effectiveness
of the care pathway;
3. Qualitative study with patients who received the inter-
vention to explore their experiences of the care pathway.
Design
Core trial information are presented in Appendix – WHO
Trial Registration Data Set. This is a pragmatic, parallel,
two-arm, superiority, multi-centred randomised con-
trolled trial using 2:1 intervention:control randomisation,
with an internal pilot phase and embedded economic
evaluation and qualitative studies. The trial is currently
taking place at four high-volume National Health Services
(NHS) centres for total knee replacement, and will be
expanded to include 8–10 trial sites.
Regulatory approvals
Ethics approval was obtained from South West – Central
Bristol Research Ethics Committee in July 2016 (REC
reference 16/SW/0154) and HRA approval in August
2016. Any protocol amendments will be submitted to the
HRA for approval prior to implementation and updated
on the ISRCTN registry.
Fig. 1 SPIRIT Figure for the schedule of enrolment, interventions and assessments
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Patient involvement in trial design
Patients were involved in trial design through the University
of Bristol’s Musculoskeletal Research Unit’s ‘Patient Experi-
ence Partnership in Research’ (PEP-R) patient involvement
groups [32]. The PEP-R Musculoskeletal group comprises
nine patients with musculoskeletal conditions, most of
whom have had joint replacement. The PEP-R STAR group
is a specialised group established for this programme of
work, comprising five patients with experience of chronic
pain after knee replacement. Both of these groups inputted
into trial design, acceptability of randomisation, design of
data collection and primary outcomes, questionnaires,
patient information leaflets, recruitment consultations and
qualitative topic guides.
Patient recruitment
A diagram of participant flow in the trial is provided
in Fig. 2.
Eligibility criteria
Inclusion criteria are adults aged ≥ 18 years who have
received a primary total knee replacement because of
osteoarthritis at a participating NHS Trust and who
report pain in their operated knee at 2–3 months after
surgery, assessed using the 7-item pain subscale of the
Oxford Knee Score (OKS) [35] (each item on the OKS is
scored 0–4, with a total pain score of 0–28, severe pain
to no pain). Based on previous cluster analysis [36],
patients with pain are defined as those with a score of
0–14 on the OKS pain subscale.
Exclusion criteria are a lack of capacity to provide in-
formed consent to participate, previous participation in
the STAR trial for the contralateral knee, or participation
in another research study that interferes unacceptably
with the STAR trial.
Screening process to identify patients with chronic pain
after knee replacement
An NHS employee will search hospital computer systems
to identify all patients who had received a primary total
knee replacement for osteoarthritis 2 months previously.
These individuals will be sent a pre-screening notification
card; 2–4 days later, they will be sent a screening study
pack. Anonymised data on the age and sex of all patients
sent a screening pack will be recorded. The screening pack
includes a cover letter, patient information leaflet, screening
questionnaire, a freepost envelope and a complimentary
teabag. One reminder screening pack will be sent if no
response is received within 1–2 weeks. Patients are asked
to complete and return the screening questionnaire and
consent form. On receipt of a completed screening
questionnaire, the research team scores the OKS to identify
patients with pain in their replaced knee (score of 0–14 on
the OKS pain subscale).
Fig. 2 Participant flow through the trial
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Recruitment process
Patients who score 0–14 on the screening OKS pain sub-
scale and consent to further contact from the research team
will be posted a trial information pack and then telephoned
by a researcher 3–5 days later. If participating, they will
then complete a second OKS via telephone with the
researcher to ensure they still meet the inclusion criteria for
the trial. A face-to-face recruitment consultation at the par-
ticipant’s home or local hospital is then arranged. Some of
the final detailed aspects of this recruitment consultation
will be informed by work during the pilot phase of the trial
and will follow a model consultation process [37]. If a pa-
tient would like to participate in the trial, they will be asked
to provide informed, written consent. All patients will be
provided with a sheet of publicly available contact details
for relevant charities or organisations, such as Arthritis
Care, Pain Concern and Mind. Participants are then given a
baseline questionnaire to complete and return to the
research team. All researchers involved in recruitment have
Good Clinical Practice and trial-specific training.
Randomisation
After participants have provided written, informed consent
and have returned a completed baseline questionnaire, they
will be randomly allocated to the STAR pathway or usual
care. Participants will be informed of their allocation by a
member of the research team. Randomisation occurs as
soon as possible after the baseline questionnaire is received.
Randomisation with allocation concealment is conducted
remotely via the Bristol Randomised Trials Collaboration
using a web-based randomisation system. Randomisation
takes place on a 2:1 basis to ensure that the intervention
service is running at sufficient capacity to enable a prag-
matic assessment of its clinical and cost-effectiveness.
Moreover, if the intervention is operating to a sufficient
degree of capacity, then per-protocol and Complier Average
Causal Effect analyses will be more reliable and have higher
power. To ensure reasonable balance between the two
treatment groups, allocation is minimised by pain severity
and pain interference scores for the replaced knee (assessed
with the Brief Pain Inventory Severity and Interference
Scales and categorised into tertiles based on data from a
previous study [30]), and stratified by trial centre.
Blinding of participants and trial personnel to treat-
ment allocation is not possible due to the nature of the
intervention. After participants have been randomised,
the research team will send the participant and their
General Practitioner (GP) a letter to inform them of
treatment allocation.
Usual care
All patients in the trial receive usual care as provided by
their hospital. The trial sites all provide a routine 6-week
postoperative follow-up, and one centre provides an
additional 3-month appointment. All centres provide
additional follow-up with a surgeon if requested but do
not include routine follow-up by practitioners specialis-
ing in pain.
Intervention
Participants randomised to the intervention group will
receive usual care and the STAR intervention, which
consists of a 1-hour-long assessment clinic appointment
with a trained Extended Scope Practitioner (a registered
allied healthcare professional with specialist training in
orthopaedics) and up to six telephone follow-up calls
over 12 months (Fig. 3). Adherence to the intervention
is defined as attendance at the assessment clinic appoint-
ment. Participants will be offered an assessment clinic
appointment as soon as possible after randomisation,
ideally within 1 week. Booking an appointment is
arranged over the telephone and confirmed by letter.
The clinic appointment is booked for 1 hour and in-
volves the Extended Scope Practitioner taking a clinical
history, reviewing patient-reported outcome measures,
conducting a knee examination, and reviewing radio-
graphs and blood test results. Patient-reported outcome
measures include the Brief Pain Inventory (BPI) [38],
Hospital Anxiety and Depression Scale (HADS) [39],
painDETECT [40] and Douleur Neuropathique 4 (DN4)
[41]. The knee examination involves evaluating the sites
and nature of knee tenderness, surgical wound healing,
range of motion, alignment, stability, patellofemoral joint
function, signs of infection, and signs and symptoms of
Complex Regional Pain Syndrome as per the Budapest
criteria [42]. A blood sample is taken to test for markers
of infection. Participants have anteroposterior long leg
alignment, lateral, and patella skyline knee radiographs
taken if these have not already been performed as part
of their usual care to evaluate alignment and assess for
evidence of fracture or concerns with sizing, fixation or
position of the implants. The appointment may last lon-
ger than 1 hour since additional time is required for
radiographs.
Findings from the assessment clinic appointment are
recorded on a standardised proforma and entered into
the research database. On the basis of the STAR assess-
ment, participants are referred to appropriate existing
services for further treatment, which may include one or
more of the following: a surgeon, when pain is attribut-
able to surgical factors; physiotherapy for exercise and
mobility advice and support; a GP for treatment of
depression or anxiety; and/or pain specialists for neuro-
pathic pain or Complex Regional Pain Syndrome (via
GPs). Monitoring is also available if this is appropriate.
The STAR care pathway is individualised and flexible,
and other referrals can be made depending on the needs
of the participant. Copies of all referral letters are sent
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to the patient, their treating orthopaedic surgeon and
their GP.
Participants receive telephone follow-up from the
Extended Scope Practitioner based on clinical need, up
to a maximum of six times over 12 months. These
telephone calls are to follow-up on the received and to
ensure that any referrals are being undertaken. Addition-
ally, further referrals can be made on the basis of these
telephone follow-up consultations. Details of these tele-
phone calls and any additional referrals made after the
follow-up telephone call are documented on a standar-
dised proforma.
All Extended Scope Practitioners delivering the inter-
vention attend a 1-day training session and are provided
with a comprehensive intervention training manual that
includes standard operating procedures for the assess-
ment. Further details of the development and content of
the intervention, in line with the template for interven-
tion description and replication (TIDieR) [43], has been
published separately.
Minimisation of contamination
It is possible that evolution of usual care over time
may be influenced by implementation of the interven-
tion at participating sites. To minimise this risk, we
will liaise with the Principal Investigators and key
trial staff at each site to ensure that information
about the trial is disseminated to local clinical staff,
taking care that this is not counterproductive. The
provision of usual care will be monitored through re-
source use questions in the follow-up questionnaires
at 6 and 12 months after randomisation.
Co-treatments
Participants can seek treatment for related or unrelated
medical conditions as needed during the trial. Use of
health services are recorded in follow-up questionnaires
and will be used in the health economics analysis.
Assessment of intervention fidelity
Intervention fidelity evaluates the degree to which an
intervention is delivered as intended [44]. In this trial,
assessment clinics and telephone follow-up calls will be
observed to evaluate if the intervention is being deliv-
ered as intended in the intervention training manual. A
minimum of one assessment clinic for each Extended
Scope Practitioner involved in intervention delivery will
be observed annually. Observations are recorded on a
standardised proforma and any additional training needs
are highlighted and actioned.
Outcome measurement
All participants are assessed at baseline prior to ran-
domisation (3 months after surgery) and at 6 months (9
months after surgery) and 12 months (15 months after
surgery) after randomisation. All outcome measure-
ments will be undertaken via self-report questionnaires
and participants are provided with a complimentary tea-
bag with each questionnaire. Participants are offered the
option of completing study questionnaires on paper or on-
line through REDCap (https://www.project-redcap.org/).
If completed questionnaires are not received within 2
weeks, a reminder questionnaire will be sent. If no
response is received to the reminder, a researcher will
telephone the participant to offer support in completing
the questionnaire on the telephone. Telephone calls to
Fig. 3 Schematic overview of STAR care pathway
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participants who do not return a follow-up question-
naire will be performed by a researcher from a different
trial centre to ensure that the researcher is blinded to
treatment allocation.
The primary and secondary outcomes map directly
onto the eight domains of the core outcome set for the
assessment of chronic pain after knee replacement [45].
Details of the time point for each outcome are provided
in Fig 1. The co-primary outcomes are pain severity and
pain interference assessed using the BPI [38] at 12
months after randomisation. Participants will be asked
to complete the BPI in relation to their operated knee.
Secondary outcomes include:
 Pain and physical functioning: OKS [35]
 Neuropathic pain: PainDETECT [40] and DN4 [41]
 Psychological status: HADS [39], Pain
Catastrophizing Scale [46], and Possible Solutions to
Pain Questionnaire [47]
 Use of pain medications: Resource use questions (to
be analysed as part of the cost-effectiveness analysis)
 Improvement and satisfaction with pain relief:
Self-Administered Patient Satisfaction Scale [48],
single-item question on comparison of pain to
pre-operative pain
 Temporal aspects of pain: Single-item questions on
pain frequency during past 24 h and 4 weeks.
 Capability: ICECAP-A [49]
 Health-related quality of life: EQ-5D-5 L [50] and
Short Form-12 [51]
 Pain elsewhere: body diagram to assess chronic
widespread pain [52]
Mean/median scores at 12 months post randomisation
will be analysed for continuous outcomes. The HADS
and the single-item questions on pain frequency and
comparison to pre-operative pain will be analysed as
ordinal variables. Pain elsewhere will be treated as a
dichotomous outcome, with patients defined as having
chronic widespread pain if they report pain in at least
two sections of each two contralateral limbs and in the
axial skeleton.
The final questionnaire includes free-text questions
that ask participants to explain what has and has
not helped with their knee pain over the duration of
the trial.
Resource use
Resources used in relation to the intervention (includ-
ing initial face-to-face assessment and telephone con-
tacts) will be recorded on a standardised proforma. Use
of health services including primary, secondary and
tertiary care, use of personal social services and
additional costs (private healthcare, travel, lost income,
home modifications) will be collected in the follow-up
questionnaires at 6 and 12 months after randomisation.
Participants are provided with resource diaries and pre-
scribed medication folders to prospectively record and
document any health resources they have used to assist
them in the completion of the questionnaires [53].
Resource use data, including inpatient stays and out-
patient visits for all participants at the treating hospi-
tals, will be obtained from hospital electronic systems
or extracted from hospital records and recorded on a
standardised proforma.
Internal pilot phase
The 6-month internal pilot phase at four trial sites
will evaluate patient identification and eligibility,
recruitment rates, withdrawal rates and reasons for
withdrawal, questionnaire completion rates, adverse
reactions and protocol compliance. Embedded qualita-
tive research, involving audio-recording of recruitment
consultations and telephone interviews with partici-
pants, will be undertaken to optimise recruitment and
trial processes. Anonymised transcripts from the
recruitment consultations and interviews will be
imported into the qualitative data management soft-
ware QSR NVivo™. Data will be analysed thematically,
involving inductive and deductive coding and categor-
isation [54]. Data from the pilot phase will be used to
inform refinements to recruitment and trial processes.
Patients recruited into the pilot phase will continue
with the follow-up schedule and be retained in the
full trial analysis.
Safety
Data on adverse events reactions (adverse events
directly attributable to the intervention) are collected
and closely monitored to ensure the ongoing safety
of participants. All serious adverse events will be
notified to the study sponsor and reviewed by the
Trial Steering Committee.
Withdrawals
Participants are free to withdraw from the trial at any
point. All withdrawals will be recorded on a standardised
form. Those who withdraw from the trial will be asked if
they would be willing to discuss their reasons for with-
drawal to allow the identification of any barriers to par-
ticipation and highlight whether measures to facilitate
participation in the trial need to be implemented.
Qualitative study
After the 12-month follow-up, a purposive sample of up
to 30 participants from the intervention group will be
interviewed about the STAR care pathway. This sample
size should be sufficient to achieve data saturation in
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keeping with standards of qualitative research [55, 56].
Interviews will address participants’ experiences of the
pathway and their experience of surgery, pain, and re-
source use. With participants’ consent, interviews will be
audio-recorded and anonymised transcripts imported
into QSR NVivo™ and analysed using a thematic ap-
proach [54]. Findings will be used to further inform the
interpretation of the trial’s findings as well as implemen-
tation into clinical practice.
Thank you cards and newsletters
Cards will be sent to participants at 3 and 9 months
after randomisation to thank them for their continu-
ing involvement in the STAR trial and to remind
them when they can expect to receive the next STAR
questionnaire. Newsletters will be sent to all partici-
pants every 6–12 months to keep them updated on
trial progress.
Sample size
For a 2:1 intervention:control randomisation ratio, a
sample size of 285 patients would have a power of
80% to 90% to detect standardised differences of
between 0.35 and 0.40 standard deviations using a
two-sided 5% significance level. From previous studies
[57, 58], the standard deviations for each of the BPI
Interference and Pain Severity scales for patients with
chronic post-surgical pain have been observed to be
approximately 2, in which case, the target effect size
translates to a difference between intervention and
control groups of between 0.7 and 0.8 scale points
for both scales. Such a difference is worthwhile
detecting clinically, since the current consensus state-
ment indicates that differences of approximately one
scale point can be deemed the minimally important
difference for both of these scales [58, 59]. To allow
for a conservative 25% loss to follow-up in the STAR
trial, 381 participants will be recruited.
Data management
Participants’ personal data will be regarded as strictly
confidential and will be entered onto a secure adminis-
trative Microsoft Access™ database stored on a Univer-
sity of Bristol server. Only STAR team members with
appropriate contracts/letters of access with NHS trusts
will have access to participants’ personal data. Anon-
ymised trial data will be stored using REDCap, an online
secure application [60]. REDCap will also be used to
administer online questionnaires to trial participants.
Double data entry of the primary outcome measure for
all participants completing paper questionnaires and full
Case Report Forms for a random sample of participants
will be undertaken to ensure data quality.
Data monitoring
The trial will be overseen by an independent Trial
Steering Committee (TSC), composed of four clinical
or non-clinical academics and one member of the
public. The TSC will meet at regular intervals to re-
view trial progress, protocol adherence and patient
safety. The TSC decided that a Data Monitoring
Committee was not necessary for this trial and that
safety data and data quality will be reviewed by the
TSC. No formal interim analysis will be conducted;
however, data from the pilot phase were analysed to
evaluate the feasibility of proceeding to the main trial.
The trial will be stopped earlier than planned if man-
dated by the NHS Ethics Committee, recommended
by the TSC, funding for the trial ceases or for any
other relevant major clinical or therapeutic reason.
Auditing
The coordinating centre will regularly monitor trial sites
to ensure data quality and completeness. The trial
sponsor (North Bristol NHS Trust) will monitor the
trial, potentially including reviewing the Site Files and
participants’ medical records.
Statistical analysis
The full statistical analysis plan for the STAR trial
can be accessed at the University of Bristol publica-
tions repository [61]. Data analysis will be conducted
in accordance with CONSORT guidelines, commen-
cing with descriptive analyses to compare groups at
baseline. The primary comparative analysis will apply
the intention-to-treat principle including all partici-
pants as randomized and with primary outcome data
available at 12 months after randomisation. The mean
BPI pain severity and BPI interference scores at 12
months after randomisation will be compared be-
tween the usual care and intervention groups using
linear regression models, adjusting for the respective
baseline score and the minimisation/stratification vari-
ables. Sensitivity analyses will use standard imputation
techniques to impute missing primary outcome data.
The secondary outcomes will be analysed using re-
gression models in a similar manner to the primary
analysis. Subgroup analyses will investigate variation
in the treatment effect between orthopaedic centres
and by pain severity, using interaction terms added to
the regression models. Explanatory analyses, such as
Complier Average Causal Effect methodology, will be
used to estimate the effect in those patients able to
comply with their allocated intervention. Compliance
in the intervention group is defined as attendance at
the STAR assessment clinic.
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Cost-effectiveness analysis
The primary cost-effectiveness analysis will take an NHS
and Personal Social Services perspective. A secondary ana-
lysis will take a broader perspective to include patients’ costs.
Only resources used in relation to the treatment of chronic
pain will be measured from randomisation to 12 months
follow-up. All resources will be valued using routine data
sources and information from hospital finance departments.
All analyses will be on an intention-to-treat basis and there
will be no discounting of costs or effects given the 1 year
duration of the study. The primary outcome for the eco-
nomic evaluation will be the Quality Adjusted Life Year
(QALY). The difference in costs and QALYs between the
arms will be assessed using the Net Benefit framework using
appropriate regression models adjusted for baseline values
of the minimisation/stratification variables. Additionally, the
difference in costs and those in primary outcomes will be
examined. If no arm is dominant, then incremental cost-
effectiveness ratios will be calculated using, if appropriate,
Seemingly Unrelated Regressions to account for the poten-
tial correlation between costs and the primary outcomes.
Given the number of important secondary outcomes, a cost
consequence analysis will also be conducted in relation to
these outcomes. Uncertainty will be addressed using cost-
effectiveness acceptability curves and sensitivity analyses.
Dissemination policy
Publications will include a final report, presentations at
scientific meetings and open-access articles in peer-
reviewed journals. Avenues for disseminating findings to
patients and the public will be identified and developed
in collaboration with the PEP-R patient involvement
groups and relevant charity organisations such as
Arthritis Care. In addition, all participants who indicate
that they wish to receive study results will be sent a plain
English summary of the final results.
Discussion
To our knowledge, this is the first randomised con-
trolled trial to evaluate the clinical and cost-effectiveness
of a care pathway when compared with usual care for
patients screened as having early indications of chronic
pain after total knee replacement. The care pathway
aims to identify the potential causes of pain to enable
early appropriate onwards referral to existing services
for targeted and individualised treatment to improve
pain management and to reduce the impact of pain. The
design and development of this complex intervention
has been informed by multiple stages of work [30], in
line with Medical Research Council guidance on the de-
velopment of complex interventions [62].
There are practical and operational issues pertinent
to this trial, particularly regarding screening and ran-
domisation of patients. Approximately 1 in 5 patients
experience chronic pain after total knee replacement
and therefore this trial involves a stage of screening to
identify this subgroup early in the postoperative period.
An issue is that patients with poorer outcomes after
joint replacement are less likely to respond to postal
questionnaires [63]. A Cochrane review identified a
number of strategies to improve response rates to ques-
tionnaires [64], and we have implemented a number of
these, including pre-notification screening cards and
non-monetary incentives in the form of a teabag to
indicate that the study team appreciate that completion
of trial questionnaires requires time and effort from the
participant.
In this trial, we are randomising patients on a 2:1
intervention:control allocation ratio. Justification for the
use of unequal randomisation allocation is often poorly
reported [65]. There are numerous reasons given for the
use of unequal randomisation ratios, including to reduce
costs, improve recruitment, increase the amount of
information on the new treatment including safety data,
and to account for differential loss to follow-up and
cross-over [65–67]. In this trial, randomisation will take
place on a 2:1 basis to ensure that the intervention
service is running at sufficient capacity to enable a prag-
matic assessment of its effectiveness and, particularly,
cost-effectiveness. Providing potential participants with
an explanation for the reasons behind 2:1 randomisation
is important to ensure that equipoise is conveyed
adequately. To address this concern, we are undertaking
patient involvement activities and qualitative research
within the internal pilot phase with the aim of improving
the verbal and written information we provide to poten-
tial participants about randomisation.
The findings of this trial will provide evidence to guide
decisions by clinicians, policymakers and patients, and
to inform commissioning of services. If shown to be
clinically and cost-effective, this intervention could
improve the early identification and management of
chronic pain after total knee replacement. It is also pos-
sible that this model of care delivery could be adapted
for the evaluation of the management of chronic post-
surgical pain in other surgical contexts.
Trial status
The first participant was recruited into the trial in
October 2016. Recruitment is scheduled to be com-
pleted by March 2019, and follow-up and data col-
lection are scheduled to be completed by March
2020.
Additional file
Additional file 1: SPIRIT checklist. (DOCX 23 kb)
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Appendix
Table 1 World Health Organization Trial Registration Data Set
Item number Item Description
1 Primary registry and trial identifying number ISRCTN92545361
2 Date of registration in primary registry 30/08/2016
3 Secondary identifying numbers REC reference: 16/SW/0154
NIHR Programme Grant for Applied Research reference: RP-PG-0613-20,001
4 Sources of monetary or material support NIHR Programme Grant for Applied Research
5 Primary sponsor North Bristol NHS Trust
Research and Innovation, Learning and Research Building, Southmead Hospital,
Bristol, BS10 5NB
Tel: 0117 414 9330
E-mail: research@nbt.nhs.uk
6 Secondary sponsor Not applicable
7 Contact for public queries Wendy Bertram
Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School,
University of Bristol
Learning & Research Building, Southmead Hospital, Bristol, BS10 5NB
Telephone: 0117 414 7848
E-mail: wendy.bertram@bristol.ac.uk
8 Contact for scientific queries As above
9 Public title Evaluation of a care pathway for patients with long-term pain after knee replacement
10 Scientific title Evaluation of the clinical and cost-effectiveness of a care pathway for patients
with chronic pain after total knee replacement: STAR trial
11 Countries of recruitment UK
12 Health condition(s) or problem(s) studied Chronic pain after total knee replacement
13 Intervention(s) Intervention group: One-hour STAR assessment clinic with an Extended Scope
Practitioner to identify potential causes of pain and enable onwards referral to
appropriate existing services. Up to 6 telephone follow-up calls from the Extended
Scope Practitioner over the 12 month follow-up period.
Control group: Care as usual
14 Key inclusion and exclusion criteria Age: 18 years or over; no upper age restriction
Sex: Male or female
Inclusion: Patients who have received a primary total knee replacement because of
osteoarthritis at a participating NHS Trust and who report pain in their operated knee
at 2–3 months after surgery (score of 0–14 on the Oxford Knee Score pain subscale).
Exclusion: A lack of capacity to provide informed consent to participate, previous
participation in the STAR trial for the contralateral knee, participation in another
research study that interferes unacceptably with the STAR trial
15 Study type Interventional
Allocation: Randomised
Assignment: parallel
Phase III
16 Date of first enrolment October 2016
17 Target sample size 381
18 Recruitment status Recruiting
19 Primary outcomes Pain intensity and pain severity at 12 months after randomisation, measured
using the Brief Pain Inventory
20 Key secondary outcomes Brief Pain Inventory at 3 and 6 months after randomisation
Oxford Knee Score at 3, 6 and 12 months after randomisation
painDETECT at 3, 6 and 12 months after randomisation
Douleur Neuropathique 4 at 3, 6 and 12 months after randomisation
Hospital Anxiety and Depression Scale at 3, 6 and 12 months after randomisation
Pain Catastrophizing Scale at 3, 6 and 12 months after randomisation
Possible Solutions to Pain Questionnaire at 3, 6 and 12 months after randomisation
Self-Administered Patient Satisfaction Scale at 3, 6 and 12 months after randomisation
ICECAP-A at 3, 6 and 12 months after randomisation
EQ-5D-5 L at 3, 6 and 12 months after randomisation
SF-12 at 3, 6 and 12 months after randomisation
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